Sort   by:  
 Page size 
UnknownRandomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
Not available
S-EPMC3138719 | biostudies-literature
TranscriptomicsGene expression signature reflects differentiation differences rather than telomere maintenance mechanism
A gene expression signature purporting to distinguish between telomerase and ALT immortalization has recently been described (Lafferty-Whyte et al., 2009). This was obtained as the intersection of two independent signatures, one obtained from cell lines and the other from a panel of liposarcomas, w...
ORGANISM(S): Homo sapiens 
2010-03-06 | E-GEOD-20559 | biostudies-arrayexpress
UnknownPathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
Not available
S-EPMC4026579 | biostudies-literature
UnknownEfficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Not available
S-EPMC3675695 | biostudies-literature
UnknownEfficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Not available
S-EPMC5070559 | biostudies-literature
TranscriptomicsDoxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with ALT
Soft tissue sarcomas are a diverse set of fatal human tumors where few agents have demonstrable clinical efficacy, with the standard therapeutic combination of doxorubicin and ifosfamide showing only a 25-30% response rate in large multi-institutional trials. Although liposarcomas are the most commo...
ORGANISM(S): Homo sapiens 
2010-03-03 | E-GEOD-19449 | biostudies-arrayexpress
UnknownSwitch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
Not available
S-EPMC7526717 | biostudies-literature
ProteomicsCombined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor
AKT activation is a hallmark of IM resistance in GIST. The presence of an additional therapeutic agent could potentially suppress the growth and survival of a clone of cancer cells, which have developed resistance to IM. Simultaneous targeting of AKT in addition to inhibiting KIT with IM has potenti...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2021-01-20 | MSV000086739 | MassIVE
UnknownRipretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Not available
S-EPMC9746771 | biostudies-literature
UnknownRipretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
Not available
S-EPMC9362852 | biostudies-literature
Sort   by:  
 Page size